# INVESTMENT COMMITTEE DECISION: MMC (Marsh McLennan)
# R4 — 10 Gates Evaluation
# Date: 2026-02-14

---

## PASO 0: SKILLS AND FILES LOADED

- [x] learning/principles.md — 9 principles internalized
- [x] learning/decisions_log.yaml — precedents reviewed
- [x] world/current_view.md — macro context (2026-02-11)
- [x] world/sectors/insurance.md — sector view verified (2026-02-13)
- [x] portfolio/current.yaml — 11 positions, EUR 5,752 cash (~57%)
- [x] .claude/skills/investment-rules/SKILL.md
- [x] .claude/skills/quality-compounders/SKILL.md
- [x] .claude/skills/portfolio-constraints/SKILL.md
- [x] .claude/skills/business-analysis-framework/SKILL.md
- [x] .claude/skills/valuation-methods/SKILL.md
- [x] .claude/skills/exit-protocol/SKILL.md
- [x] thesis/research/MMC/thesis.md — R1 fundamental analysis
- [x] thesis/research/MMC/moat_assessment.md — WIDE 21/25
- [x] thesis/research/MMC/risk_assessment.md — MEDIUM-HIGH, 4 HIGH risks
- [x] thesis/research/MMC/valuation_report.md — FV $190, entry $160
- [x] thesis/research/MMC/devils_advocate.md — 13/20 MODERATE COUNTER

---

## PASO 0.5: PRECEDENTES CONSULTADOS

### Most Similar Precedents

**1. ROP (Roper Technologies) — Standing Order BUY at $300**
- Tier: B (upper), QS 70 adjusted (+22 serial acquirer)
- MoS: 22% at $300 vs FV $385
- Sizing: 4% (~EUR 400)
- Conviction: Low
- Context: Serial acquirer, goodwill-distorted ROIC, elevated leverage, WIDE moat (20/25), 2 CRITICAL risks
- Outcome: Standing order pending, not triggered yet
- **Relevance:** Very high. Both are Tier B with elevated debt from large acquisitions, WIDE moats, and standing order evaluations. ROP had 2 CRITICAL risks vs MMC's 4 HIGH risks.

**2. ACGL (Arch Capital) — R1 WATCHLIST at $92**
- Tier: B, QS 68 adjusted
- MoS: 23% at $92 vs FV $120
- Context: Same insurance sector, same QS as MMC, underwriter (not broker)
- **Relevance:** High. Same sector, same QS, same tier. ACGL has cleaner balance sheet but is an underwriter (cyclical claims risk). MMC has no claims risk but has Greensill litigation.

**3. BYIT.L (Bytes Technology) — BUY at 296p**
- Tier: A (at time of purchase, later revised to B)
- QS: 81 (later revised to 68-72)
- MoS: 35% at purchase
- Sizing: 3.5%
- **Relevance:** Moderate. Similar in that BYIT was purchased as Tier A but revealed as Tier B after adversarial review. MMC is honestly Tier B from the start.

### Consistency Check

If I approve MMC as a standing order at $155 with ~18.4% MoS for Tier B (QS 68):

| Precedent | Tier | QS | MoS | Risks | Approved? |
|-----------|------|-----|-----|-------|-----------|
| ROP | B | 70 | 22% | 2 CRITICAL | YES (standing order $300) |
| ACGL | B | 68 | 23% | MEDIUM | YES (watchlist $92) |
| MMC | B | 68 | 18.4% | 4 HIGH | Evaluating now |

MMC's 18.4% MoS is 3.6pp below ROP (22%) and 4.6pp below ACGL (23%). However:
- MMC has WIDE moat (21/25) vs ROP (20/25) — slightly better moat
- MMC has NO underwriting risk (unlike ACGL which has cat exposure)
- MMC has 85%+ recurring revenue (most predictable of the three)
- MMC has Greensill tail risk that neither ROP nor ACGL has

**Deviation analysis:** The lower MoS is partially justified by the higher revenue predictability and stronger moat, but partially NOT justified by the Greensill tail risk. The R3 resolution addressed this by making Greensill a SIZING CONSTRAINT (half position at entry, full only after resolution). This is a reasonable compromise — lower MoS compensated by lower position sizing.

---

## GATE 0: SECTOR VIEW EXISTS

```
Sector: Insurance (broking)
File: world/sectors/insurance.md
Last updated: 2026-02-13
Status: NEUTRAL — Stock picking selectivo
MMC specifically covered as "top insurance BROKER pick"
Broker vs Underwriter distinction: PRESENT in sector view (added 2026-02-13)
```

**VERDICT: PASS**

Sector view exists, is current (updated yesterday), explicitly covers MMC, and distinguishes between brokers and underwriters — a critical distinction for this evaluation.

---

## GATE 1: QUALITY SCORE

```
QS Tool: 64/100 (Tier B)
QS Adjusted: 68/100 (Tier B) — +4 for market position (#1 global, 15 consecutive years)
Tier: B
```

**Adjustment rationale (+4 points):**
The quality_scorer.py assigns 0/8 for Market Position because it requires manual input. MMC is indisputably the #1 global insurance broker for 15 consecutive years with revenue 63% larger than #2 Aon ($27B vs $16.6B). The DOJ blocking Aon-WTW merger in 2021 confirmed the oligopoly. This warrants 8/8 market position points. The net adjustment is conservative at +4 (not the full +8 implied gap) because some market position benefit is already captured through GM premium and ROIC persistence scores.

**Why not Tier A (>=75)?**
- Leverage 2.4x penalizes financial quality (5/10 vs 10/10 for net cash)
- ROIC spread +6.6pp is good but below the 15pp maximum threshold (for brokers, ROE 27% is more relevant but QS framework weights ROIC)
- Revenue CAGR 9.2% includes inorganic growth; organic is only 4%
- Insider ownership 0.1% gets 0 points

**QS Tool-First compliance:** Both scores shown. Adjustment is +4 with documented evidence. Adjustment < 5 points — no additional evidence barrier required.

**Tier D check:** QS 68 >> 35. Not Tier D.

**VERDICT: PASS** — QS 68, Tier B. Proceed.

---

## GATE 2: BUSINESS UNDERSTANDING

**Can I explain this business in 2 minutes?**

MMC is the world's largest insurance broker — it connects companies that need insurance with insurance carriers. Unlike insurers (ALL, GL), MMC never takes risk on its own balance sheet. It earns commissions (% of premiums placed) and advisory fees. The business has four segments: Marsh (large commercial broking, 53%), Guy Carpenter (reinsurance broking, 9%), Mercer (HR consulting, 24%), and Oliver Wyman (management consulting, 14%). About 85% of revenue is recurring because insurance policies renew annually with 90%+ retention rates. The company has grown revenue every year for 30+ years except one year during 2008-09. It is #1 globally, 63% larger than #2, with a moat protected by switching costs, scale, data advantages, and a regulatory oligopoly (DOJ blocked #2 merging with #3).

**Why is it cheap?**
1. Insurify ChatGPT app launched Feb 9, 2026 triggered -7% selloff (narrative: AI will disintermediate brokers). But Insurify targets personal auto, not Fortune 1000 complex commercial — completely different markets.
2. Organic growth decelerated from 7% to 4% as insurance rates soften.
3. $7.75B McGriff acquisition elevated debt to 2.4x EBITDA.
4. Multiple compressed from 28-30x to 22x P/E.

**Counter-thesis to "cheap":**
- 4% organic growth may be the "new normal" not a trough (management guided "similar" for 2026)
- Consulting segment (35% revenue) IS more vulnerable to AI than broking
- Greensill A$7B trial in August 2026 is genuine binary risk
- BofA downgraded to Underperform with $181 PT

**Value trap checklist: 0-1/10** (partial flags on leverage and goodwill from acquisitions, both manageable)

**Business Analysis Framework completed:** Yes — unit economics, revenue quality, capital intensity, macro sensitivity all documented in thesis.

**Informational advantage:** Time horizon (market pricing cyclical trough as secular decline) + structural misunderstanding (market conflating brokers with insurers on AI risk).

**VERDICT: PASS** — Business is well understood. Counter-thesis is documented and addressed.

---

## GATE 3: PROJECTION FUNDAMENTADA

**Revenue growth derivation:**
- Insurance brokerage TAM growth: 4-5% (US 4.1%, global 9.4% CAGR)
- Market share: Stable to gaining (#1, consolidating via McGriff)
- Pricing: +1-2% (commissions tied to premium rates)
- Inorganic: +2-3% (McGriff annualization + bolt-on M&A)
- **Total: ~7% (4% organic + 3% inorganic)**

Not a default. Derived from TAM/share/pricing analysis.

**WACC derivation:**
- Rf: 4.3% (10Y UST)
- ERP: 5.5% (Damodaran)
- Beta: 0.75 (yfinance)
- Ke: 8.4%
- Kd (pre-tax): 4.5%, after-tax: 3.4%
- D/V: 19%, E/V: 81%
- **WACC: 7.5% (derived), 8.5% (used with +1pp conservatism for McGriff debt risk)**

Not a default. Calculated from components.

**Terminal growth: 2.5%** — Below GDP, conservative for insurance brokerage TAM growing 4-9%.

**Scenarios documented:**

| Scenario | FV | Prob | Drivers |
|----------|-----|------|---------|
| Bear | $148 | 25% | Organic stalls 2-3%, consulting downturn, multiple to 15x, Greensill |
| Base | $190 | 50% | 4% organic + M&A, margin expansion, 17x stabilizes |
| Bull | $235 | 25% | Hard market returns, organic 6%+, multiple to 19x |

**Expected Value: $191**

**VERDICT: PASS** — Projections are bottom-up derived, not defaults. Three scenarios with probability weighting.

---

## GATE 4: VALUATION MULTI-METHOD

**Method selection per Tier B protocol:**

| Method | FV | Weight | Weighted | Rationale |
|--------|-----|--------|----------|-----------|
| EV/EBIT (17x forward) | $204 | 50% | $102 | Primary for asset-light fee business; direct peer comparison |
| DCF SBC-adjusted | $178 | 30% | $53 | Captures growth trajectory; HIGH sensitivity (130% spread) limits weight |
| P/E SBC-adjusted (20x) | $174 | 20% | $35 | Cross-check against peer multiples |
| **Weighted FV** | | **100%** | **$190** | |

**Divergence: 17%** (max $204 / min $174) — BELOW 30% threshold. Coherent.

**R3 Resolution on FV conflict:** Thesis originally stated $220, valuation-specialist independently arrived at $190 through three rigorous adjustments (SBC deduction, conservative WACC +1pp, blended growth with organic-only weighting). The R3 resolution CONFIRMED $190 as the canonical FV. The thesis header has been updated to reflect this.

**MoS Analysis:**

| Metric | Value |
|--------|-------|
| Current price | ~$224 |
| R3-resolved FV | $190 |
| R3-resolved Entry | $155 |
| MoS at $155 vs Base ($190) | 18.4% |
| MoS at $155 vs Expected ($191) | 18.8% |
| MoS at $155 vs Bear ($148) | -4.7% |

**VERDICT: PASS** — Two appropriate methods (EV/EBIT + DCF) plus P/E cross-check. Divergence 17% within acceptable range. FV conflict resolved to $190.

---

## GATE 5: MARGIN OF SAFETY (Razonado v4.0)

```
Tier: B (QS 68)
MoS at entry $155 vs Base: 18.4%
MoS at entry $155 vs Bear: -4.7%
MoS at entry $155 vs Expected Value: 18.8%
```

**Precedent comparison:**

| Precedent | Tier | QS | MoS | Moat | Risks |
|-----------|------|-----|-----|------|-------|
| ROP | B | 70 | 22% | WIDE (20/25) | 2 CRITICAL |
| ACGL | B | 68 | 23% | WIDE | MEDIUM |
| **MMC** | **B** | **68** | **18.4%** | **WIDE (21/25)** | **4 HIGH** |

**Is the MoS adequate for the risk?**

MMC's 18.4% MoS is below Tier B precedents (ROP 22%, ACGL 23%). I must reason explicitly about why this might be acceptable:

**Arguments FOR accepting 18.4% MoS:**
1. WIDE moat 21/25 is the strongest in the current pipeline (ROP 20/25, ACGL lower)
2. 85%+ recurring revenue makes earnings more predictable than typical Tier B
3. No underwriting/claims risk — MMC never loses money from catastrophes
4. 30+ year track record of revenue growth — this is NOT a cyclical business in the traditional sense
5. The valuation-specialist's $190 FV already incorporates SBC deduction, conservative WACC (+1pp), and blended organic/total growth — it is a CONSERVATIVELY derived FV

**Arguments AGAINST accepting 18.4% MoS:**
1. 4 HIGH risks are correlated (AI + rate softening + leverage compounding simultaneously)
2. Greensill A$7B trial in August 2026 is a genuine binary event with $500M-$1B+ potential exposure
3. BofA downgrade to Underperform with $181 PT — a major sell-side firm sees near-zero upside from current levels
4. Organic growth deceleration (7% to 4%) may be structural not cyclical
5. Bear case FV of $148 means at $155 entry, bear case loss is -4.7%

**Resolution:**

The R3 resolution already addressed this tension by (a) lowering entry from $160 to $155, and (b) making Greensill a SIZING CONSTRAINT (half position at entry). This combination effectively provides:
- 18.4% MoS for the first half-position
- Full position only AFTER Greensill resolution (by which time price may be different)
- If Greensill goes badly and stock drops, we only have half-position exposed

This is analogous to NVO's phased entry (3.4% initial with ADD conditional on CagriSema data). The precedent of conditional sizing for binary catalysts is established.

**Deviation from precedent documented:** MoS is 3.6-4.6pp below ROP/ACGL precedents. Justified by: (a) stronger moat (21/25 vs 20/25), (b) higher revenue predictability (85%+ recurring), (c) no claims risk, (d) SIZING CONSTRAINT compensates (half position limits exposure until Greensill resolved). If the Greensill trial goes favorably, the full position would be at whatever price MMC trades at then — potentially with higher or lower MoS.

**VERDICT: CONDITIONAL PASS** — 18.4% MoS is below Tier B precedents but justified by moat quality and compensated by half-position sizing constraint. The committee accepts this deviation with explicit reasoning documented.

---

## GATE 6: CONTEXTO MACRO

```
World view reviewed: 2026-02-11
Cycle: Mid-cycle US, labor market resilient, inflation sticky
```

**Fit empresa-ciclo:**
- Insurance broking is DEFENSIVE in downturns — economic uncertainty drives MORE insurance buying
- Consulting segments (35%) are MORE cyclical — recession would hit Oliver Wyman
- Fed at 3.50-3.75% stable — benefits fiduciary investment income
- Tariffs: MINIMAL direct impact (services business)
- USD weak (DXY ~96.8) — slightly positive for reported revenue (57% international) but neutral for stock valuation

**Megatendencies:**
- AI: Dual impact. POSITIVE for broking efficiency, NEGATIVE for potential disintermediation (particularly mid-market McGriff and consulting). Net: NEUTRAL for core broking, NEGATIVE for consulting
- Desglobalization: POSITIVE — trade complexity drives demand for risk advisory
- Climate change: POSITIVE for brokers — more catastrophe losses = more placement demand = higher commissions
- Activist investing: NOT applicable to MMC currently

**VERDICT: PASS** — Macro environment is NEUTRAL-FAVORABLE for insurance broking. The defensive nature of the core business (mandatory insurance, annual renewals) provides protection in uncertain macro.

---

## GATE 7: PORTFOLIO FIT (Razonado v4.0)

**Current portfolio context:**
- 11 positions, EUR ~10,092, cash EUR 5,752 (~57%)
- Tier A: 3 (ADBE, LULU, MONY.L)
- Tier B: 5 (NVO, AUTO.L, BYIT.L, EDEN.PA, DOM.L)
- Tier C: 3 (ALL, GL, DTE.DE)

**This is a standing order evaluation. MMC would only enter at $155 (~EUR 130). At that price:**

Proposed sizing: Half position initially (~EUR 200, ~2% of portfolio)

**Sector concentration:**
- Insurance current: ALL (~4%) + GL (~4%) = ~8%
- Insurance post-MMC half-position: ~10%
- But MMC is a BROKER (no claims risk), while ALL and GL are UNDERWRITERS. The correlation between broker revenue and underwriter claims is LOW — in fact, they can be inversely correlated (catastrophe losses hurt underwriters but BENEFIT brokers through placement demand)
- Reasoning: 10% insurance sector is acceptable because the sub-sectors have DIFFERENT risk profiles. A catastrophe hurts ALL but helps MMC. This is effectively diversification WITHIN the sector.

**Geographic concentration:**
- US current: ADBE (~5%), LULU (~3.5%), ALL (~4%), GL (~4%), NVO (~4% ADR) = ~20.5%
- US post-MMC: ~22.5%
- US is a developed stable market (Principle 2). 22.5% US exposure is well within prudent bounds, especially given 57% cash buffer.

**Cash post-purchase:**
- Cash: EUR 5,752 - EUR 200 = EUR 5,552 (~55%)
- Cash remains very high. This is a standing order, not immediate deployment.

**Correlation with existing positions:**
- LOW with ALL/GL (different sub-sector: broker vs underwriter)
- LOW with ADBE/BYIT.L (different sector entirely)
- MEDIUM with EDEN.PA (both professional services, but different end markets)

**Precedent sizing:**
- ROP standing order: 4% (~EUR 400) for Tier B
- MMC half-position: ~2% (~EUR 200) — consistent with "half position due to Greensill constraint"
- Full position (post-Greensill): ~4% (~EUR 400) — matches ROP precedent

**50% drawdown test:**
If MMC half-position (EUR 200) falls 50%: loss = EUR 100 = ~1% of portfolio. This is very manageable for a half-position. For full position (EUR 400): loss = EUR 200 = ~2% of portfolio. Also manageable for Tier B with WIDE moat.

**VERDICT: PASS** — Half-position sizing (~2%) is prudent given Greensill constraint. Sector concentration is acceptable because broker and underwriter risks are different. Geographic concentration is comfortable. Cash remains abundant.

---

## GATE 8: SECTOR UNDERSTANDING

```
Sector view: world/sectors/insurance.md
Last updated: 2026-02-13
Status: NEUTRAL — Stock picking selectivo
```

**Sector view coverage:**
- TAM and growth trends documented (global premiums $7.2T, brokerage TAM $328B growing 9.4%)
- Broker vs underwriter distinction EXPLICITLY documented (added for MMC analysis)
- Competitive structure detailed (Big 4 brokers, market shares, DOJ precedent)
- Rate cycle phase documented (transitioning hard-to-soft, Jan 2026 renewals -14.7% cat reinsurance)
- AI disruption risk assessed (Insurify Feb 9 selloff, personal lines vs commercial distinction)
- Reinsurance softening data current (Jan 2026 renewals)
- MMC listed as "top insurance BROKER pick" with entry $160

**The sector view was updated 2026-02-13, specifically incorporating MMC analysis and the broker/underwriter distinction.**

**VERDICT: PASS** — Sector understanding is thorough and current. The broker vs underwriter distinction is documented. Rate cycle, AI disruption, and competitive structure are all covered.

---

## GATE 9: AUTOCRITICA

**Asunciones no validadas:**
1. 4% organic growth is a cyclical trough, not the "new normal" — management guided "similar to 2025" for 2026, and BofA sees no near-term catalyst for recovery. This could persist 2-3 years.
2. McGriff integration will be successful — track record is good but this is the largest deal ever. No data on retention yet.
3. Greensill exposure is bounded at $500M-$1B — actual Marsh-specific liability within the A$7B total is unknown. Could be A$200M or A$3B.
4. AI disruption of mid-market broking (McGriff's segment) will take 3-5 years — timeline is genuinely uncertain.
5. The 17x EV/EBIT multiple is appropriate — if permanent de-rating to 15x occurs, FV drops to $160-170 (zero margin at our entry).

**Sesgos reconocidos:**
- [x] **Popularity bias**: MMC is a well-known large-cap. MITIGATED by systematic pipeline (R1+R2+R3 with 4 independent agents).
- [x] **Confirmation bias**: The thesis is compelling and I may be under-weighting the devil's advocate's concerns. MITIGATED by explicitly addressing each of the DA's 5 recommended adjustments.
- [x] **Anchoring bias**: The original thesis FV was $220 — even though resolved to $190, the "anchor" of $220 may make $190 feel conservative. MITIGATED by using $190 as canonical throughout this evaluation.
- [x] **Recency bias**: The AI selloff on Feb 9 makes MMC look like a "fallen angel" opportunity, but the selloff may be pricing in REAL structural risk, not just panic.

**Kill conditions (7 total, including 2 added per devil's advocate recommendation):**

1. Organic revenue growth turns negative for 2 consecutive quarters
2. Net Debt/EBITDA exceeds 3.5x without clear de-leveraging plan
3. ROIC falls below WACC for 2 consecutive years
4. Major regulatory action against insurance broking compensation model
5. McGriff integration fails materially (revenue leakage >20%, key talent departures >30%)
6. **Greensill adverse judgment >$1B net to Marsh** (added per DA)
7. **AI-native broker captures >2% US mid-market commercial insurance placement within 18 months** (added per DA)

**Monitoring triggers (non-kill but require reassessment):**
- Mercer + Oliver Wyman combined organic growth <2% for 2 consecutive quarters (consulting AI risk)
- Net Debt/EBITDA fails to decline below 2.0x by end 2027 (McGriff synergy delay)
- FY2026 organic growth <3% (below guided "similar to 2025")

**What would make me change my mind:**
- Greensill trial reveals fraud (not just negligence) — E&O insurance wouldn't cover, reputational damage severe
- AI disruption extends to mid-market commercial within 12-18 months (faster than expected)
- Organic growth decelerates to <2% (structural, not cyclical)
- Credit rating downgrade from A-

**VERDICT: PASS** — Self-criticism is thorough. Kill conditions are well-defined (7 total including 2 added from DA). Biases are identified and mitigated. Monitoring triggers documented.

---

## GATE 10: COUNTER-ANALYSIS & INDEPENDENT ASSESSMENTS

### Devil's Advocate (13/20 MODERATE COUNTER)

**Verdict:** MODERATE COUNTER (not STRONG). The thesis survives scrutiny as a sound business analysis but requires calibration.

**HIGH/CRITICAL challenges (3):**

1. **FV conflict ($220 thesis vs $190 valuation-specialist)**
   - **Addressed:** R3 resolved FV to $190. Thesis header updated. This gate is RESOLVED.

2. **Entry $160 provides only 16% MoS vs $190 — below Tier B precedents**
   - **Addressed:** R3 lowered entry to $155 (18.4% MoS). Combined with half-position sizing constraint for Greensill. Deviation from precedent is explicitly documented in Gate 5 with reasoning.

3. **Greensill A$7B trial (Aug 2026) is material binary risk not treated as hard gate**
   - **Addressed:** R3 made Greensill a SIZING CONSTRAINT (half position at entry, full after resolution). This is a pragmatic middle ground between "hard gate" (no entry) and "ignore" (full position). Kill condition #6 added for adverse judgment >$1B.

**MODERATE challenges resolved:**
- Organic growth 4% as new baseline: ACCEPTED. Projections use 4% organic as base case, not 7%.
- Consulting AI vulnerability: Kill condition monitoring added (Mercer+OW organic <2% for 2Q).
- McGriff mid-market AI exposure: Kill condition #7 added (AI broker >2% market share within 18 months).
- Multiple compression risk: EV/EBIT 17x already below historical 18-22x; further compression to 15x would make FV = entry (zero margin), which is the bear case.
- P&C rate softening: Accepted as multi-year headwind, reflected in base case 4% organic growth.

**Unresolved challenges: NONE** — All 5 recommended adjustments from DA have been addressed in R3 resolution.

### Moat Assessment (WIDE 21/25)

**Coincidence with thesis:** YES. Both thesis and moat-assessor classify as WIDE moat.

**Score breakdown:**
- Switching costs: 5/5 (strongest source — multi-year relationships, policy cycle lock-in, cross-selling)
- Efficient scale: 5/5 (regulatory-protected oligopoly, DOJ blocked Aon-WTW)
- Intangible assets: 5/5 (brand, 130-country licensing, proprietary data)
- Cost advantage: 3/5 (1.7x scale vs #2 but similar cost structures)
- Network effects: 3/5 (partial — data flywheel, Marsh-GC synergy)

### Risk Assessment (MEDIUM-HIGH)

**4 HIGH risks identified:**
1. AI disintermediation — ADDRESSED via kill condition #7 and monitoring
2. Greensill litigation — ADDRESSED via sizing constraint and kill condition #6
3. McGriff integration + debt — ADDRESSED via kill condition #5 and leverage monitoring
4. P&C rate softening — ACCEPTED as cyclical headwind, reflected in 4% organic growth base

**Risk correlation noted:** AI + rate softening + leverage are correlated. In bear scenario, all three compress revenue simultaneously against fixed debt burden. This is why half-position sizing is prudent.

**Risks NOT in thesis that risk assessment found:**
- CEO sold $3.8M at $182 (near current price) — noted but LOW severity
- Spitzer precedent (2004, $850M) — historical pattern of legal tail risk. Noted as context for Greensill evaluation.

### Valuation Report (FV $190)

**Divergence vs thesis:** Thesis had $220, valuation-specialist had $190. R3 resolved to $190. Divergence was 14% — driven by SBC adjustment, conservative WACC, and blended growth. RESOLVED.

**Sensitivity:** DCF FV spread 130% (HIGH). This is why EV/EBIT is primary method (50% weight). The committee notes this sensitivity and accepts it as inherent to DCF for a business with 62% terminal value.

### Conflict Resolution Between Moat-Assessor and Risk-Identifier

The moat-assessor rated AI disruption as "Low-Medium probability, Low impact." The risk-identifier rated it as "Medium probability, High impact." The devil's advocate sided with the risk-identifier.

**Committee resolution:** The risk-identifier is closer to correct for the TOTAL company. The moat is WIDE for Marsh's core large commercial broking (~55% of revenue) where AI disruption is genuinely low. But for McGriff mid-market ($2.5B, ~9%) and consulting (35%), AI risk is real and medium-term. The aggregate AI risk profile is:
- Core broking (55%): Low risk, 5-10 year horizon
- McGriff mid-market (9%): Medium risk, 3-5 year horizon
- Consulting (35%): Medium risk, 3-5 year horizon
- Guy Carpenter reinsurance (9%): Low risk, 10+ year horizon (too complex for AI)

Net: ~44% of revenue faces some AI risk within 3-5 years. This is material but not existential, and MMC is investing in AI internally (BCS unit). Kill condition #7 monitors for acceleration.

**VERDICT: PASS** — All counter-analysis challenges have been addressed. No CRITICAL unresolved issues. Moat/risk conflict resolved with explicit reasoning.

---

## FINAL VERDICT

### Gate Summary

| Gate | Verdict | Key Reasoning |
|------|---------|---------------|
| 0: Sector View | PASS | insurance.md exists, current (2026-02-13), covers MMC explicitly |
| 1: Quality Score | PASS | QS 68 Tier B. +4 adjustment documented. Not Tier D. |
| 2: Business Understanding | PASS | Business fully understood. Counter-thesis documented. 0-1/10 value trap. |
| 3: Projections | PASS | Bottom-up derived. Growth, WACC, terminal all justified. 3 scenarios. |
| 4: Valuation | PASS | 3 methods, 17% divergence. FV $190 (R3 resolved). |
| 5: Margin of Safety | CONDITIONAL PASS | 18.4% MoS below precedents (22-23%). Justified by WIDE moat + compensated by half-position sizing. |
| 6: Macro | PASS | Insurance broking is defensive. Neutral-favorable macro fit. |
| 7: Portfolio Fit | PASS | ~2% half-position. Low correlation. Adequate cash. |
| 8: Sector Understanding | PASS | Sector view thorough and current. Broker/underwriter distinction present. |
| 9: Autocritica | PASS | 7 kill conditions. Biases identified. Monitoring triggers set. |
| 10: Counter-Analysis | PASS | All DA challenges addressed. Moat/risk conflict resolved. |

### 10/10 GATES PASSED (1 conditional)

---

## RECOMMENDATION: APPROVED WITH CONDITIONS — STANDING ORDER

```
RECOMMENDATION: STANDING ORDER — MMC (Marsh McLennan)

Quality Score: 68/100 (Tier B)
Fair Value: $190 (R3-resolved, valuation-specialist weighted 3-method)
Bear/Base/Bull: $148 / $190 / $235
Expected Value: $191

Entry: $155 (18.4% MoS vs Base, 18.8% vs EV)

Sizing:
  Phase 1: EUR 200 (~2% of portfolio) at $155 — HALF POSITION
  Phase 2: EUR 200 (~2% additional) ONLY AFTER Greensill resolution
           (favorable settlement, trial outcome, or elapsed time)
  Full position: EUR 400 (~4% of portfolio) — consistent with ROP precedent

Category: Quality Value (insurance broker)
Moat: WIDE (21/25) — switching costs, regulatory-protected oligopoly, intangible assets

Risk principal: Greensill A$7B trial (Aug 2026) + correlated AI/rate/leverage headwinds
Risk level: MEDIUM-HIGH

Kill conditions (7):
  KC#1: Organic revenue growth negative 2 consecutive quarters
  KC#2: Net Debt/EBITDA >3.5x without de-leveraging plan
  KC#3: ROIC < WACC for 2 consecutive years
  KC#4: Major regulatory action against broker compensation model
  KC#5: McGriff integration fails (>20% revenue leakage, >30% talent departure)
  KC#6: Greensill adverse judgment >$1B net to Marsh
  KC#7: AI-native broker >2% US mid-market commercial within 18 months

Monitoring triggers:
  - Mercer + Oliver Wyman organic <2% for 2Q → consulting AI risk reassessment
  - Net Debt/EBITDA fails to decline <2.0x by end 2027
  - FY2026 organic growth <3%

Precedent sizing: ROP standing order (4% for Tier B WIDE moat, QS 70)
Deviation: Half-position (2%) due to Greensill sizing constraint

Standing order validity: Until Q1 2026 earnings (April 2026)
After Q1 earnings: Reassess organic growth trajectory before renewal

Confirm for standing order in state/system.yaml?
```

---

## CONDITIONS FOR APPROVAL

1. **Greensill sizing constraint is BINDING:** Do NOT deploy more than EUR 200 (~2%) at initial entry. The second EUR 200 requires either (a) Greensill settlement/dismissal, (b) trial outcome favorable to Marsh, or (c) explicit committee re-evaluation.

2. **Calendar the Greensill trial (Aug 2026)** in state/system.yaml. This is a monitored event even before entry.

3. **Monitor organic growth quarterly.** If FY2026 Q1 organic growth is <3%, the standing order should be paused pending reassessment.

4. **Update thesis header to canonical format** with `> **Fair Value:** $190` for forward_return.py parsing.

5. **Add to quality_universe.yaml** at QS 68, FV $190, Entry $155, Sector Insurance (Broker).

---

## META-REFLECTION

### Dudas sobre esta decision
- The 18.4% MoS is the lowest I have approved for Tier B. The WIDE moat and sizing constraint justify it, but if Greensill goes badly AND the market de-rates brokers further (15x), this entry could be underwater for an extended period.
- I am genuinely uncertain whether 4% organic growth is a cyclical trough or the new normal. If it is structural (broking is maturing), the entire valuation framework shifts lower.
- The devil's advocate scored 13/20 (MODERATE COUNTER), which is moderate. But 3 HIGH challenges required resolution. I resolved them through sizing constraint and kill conditions, not by lowering entry further. An alternative approach would have been entry at $145-150 (21-23% MoS, matching precedents exactly) and forgoing the Greensill sizing constraint. Both approaches are defensible.

### Debilidades del analisis recibido
- The thesis body text still references $220 FV in the scenarios section even though the header was updated to $190. This creates confusion. Should be cleaned up.
- The moat assessment rates AI disruption as "Low" impact, which is overly optimistic for the consulting segment. The risk-identifier's "High" rating is more appropriate for the aggregate company. This conflict was resolved here but the moat assessment file should note the nuance.
- Insider ownership data (0.1%) lacks granularity — we don't know management's total compensation alignment (stock grants, performance units, etc.). This is a data gap.
- Greensill litigation analysis relies on news articles, not actual 10-K disclosure. The exact reserve amounts and Marsh-specific liability share are unknown.

### Sugerencias de mejora
- The quality_scorer.py should have an adjustment flag for insurance brokers (asset-light, leveraged model where ROE is more relevant than ROIC). This would affect MMC, AON, and potentially exchanges/asset managers.
- Consider a "litigation probability tree" framework for companies with mega-litigation (>$500M potential exposure). This would standardize how we handle Greensill-type situations.
- The "half position" sizing constraint is a new pattern (first used here). If it proves useful, codify it as a standard option for binary events in the investment-committee protocol.

### Preguntas para Orchestrator
- Should the half-position sizing constraint pattern be added to the investment-committee protocol as a standard option for companies with pending binary events?
- The insurance sector view now covers both brokers and underwriters. Should these be split into separate sector views (insurance-underwriting.md and insurance-broking.md) given how different the business models are?
- ALL (ON PROBATION, QS 56 Tier C) and GL (QS 52 Tier C) are both insurance underwriters in our portfolio. With MMC (QS 68 Tier B broker) and ACGL (QS 68 Tier B underwriter) in the pipeline, should we consider rotating ALL/GL into MMC/ACGL as a quality upgrade within the insurance sector? (Principle 9: Quality Gravitation)
